Industries > Pharma > European Antibiotics Market Report 2021-2031

European Antibiotics Market Report 2021-2031

Forecasts by Drug Class (Cephalosporin, Penicillin, Fluoroquinolone, Macrolide, Carbapenem, Aminoglycoside, Sulfonamide, 7-AC, Others), by Action Mechanism (Cell Wall Synthesis Inhibitors, Protein Synthesis Inhibitors, DNA Synthesis Inhibitors, RNA Synthesis Inhibitors, Mycolic Acid Inhibitors, Others) by Gender (Male, Female), by Age (0-14 Years, 15-54 Years, 55 Years and Above), by Route of Administration (Oral, Intravenous, Others) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Antibiotics Companies AND COVID-19 Recovery Scenarios

PUBLISHED: 31 March 2021
PAGES: 726
PRODUCT CODE: PHA1127
SUBMARKET: Therapeutic Drugs

Clear
WOOCS 2.2.1
SKU: PHA1127 Categories: , Tags: ,

Rising Antimicrobial Resistance to Challenge European Antibiotics Market Growth
Antimicrobial resistance (AMR) has risen dramatically in the last 15 years, becoming a serious global issue. In France, 12 percent of Escherichia coli strains collected from blood cultures are now resistant to third-generation cephalosporins, although global resistance rates for this bacterium could range from 50 to 80 percent in some countries. Carbapenem-resistant Enterobacteriaceae have become a serious global concern in the recent decade, with rates of gram-negative bacteria topping 50% in some countries. According to WHO/Europe research reports, the European Region today faces an accelerated spread of antibiotic resistance. As a result of the COVID-19 pandemic, the long-term problem of improper antibiotic usage by individuals and in health-care settings is escalating. Despite these precautions, the hospital, like many others across Europe, has had to contend with an upsurge in antibiotic-resistant germs during the epidemic.

Contraindications of Antibiotic Resistance to Increase Alternative Antibiotic Therapies In European Market
Antibiotic-resistant microorganism infections are becoming more common and a major global problem. They may be linked to a longer stay in the hospital, higher morbidity and death, and higher costs. Overuse and misuse of antibiotics are key contributors to this problem, and the development of new effective antimicrobials is becoming increasingly constrained.

UNIQUE COVID-19 VARIATIONS– only available in this Visiongain report are dedicated analysis of 4 different rebound scenarios of how the market will develop – no matter how COVID-19 affects the economy.

To access the data contained in this document please email contactus@visiongain.com

Which Factors are Fueling European Antibiotics Industry Growth?
• Growing Burden of Infectious Diseases to Fuel Market Growth
• Rising Ageing Population Patient Pool to Drive Growth
• Adoption of Digital Health Technology to Boost Antibiotics Market Growth

Which Factors are Restraining Growth?
• Strict Regulatory Scenarios to Hamper Market Growth
• Rising Antibiotic Resistance to Restrain Market Growth

How do prominent players strengthen their position throughout the region?
You must read this newly updated report if you are involved in this sector. The report from Visiongain shows you potential revenues up to 2031, evaluate information, trends, opportunities and business outlooks.

Discover how to stay ahead
Our 720+ pages report provides 800+ tables and charts/graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall European market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing European Antibiotics Market. See how to exploit the opportunities.

Forecasts to 2031 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2031, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), SWOT Analysis, Porter’s Analysis, product profiles and commercial developments.

CTA

Discover sales predictions for the European market and submarkets

Drug Class
• Cephalosporin
• Penicillin
• Fluoroquinolone
• Macrolide
• Carbapenem
• Aminoglycoside
• Sulfonamide
• 7-ACA
• Others

Action Mechanism
• Cell Wall Synthesis Inhibitors
• Protein Synthesis Inhibitors
• DNA Synthesis Inhibitors
• RNA Synthesis Inhibitors
• Mycolic Acid Inhibitors
• Others

Gender
• Male
• Female

Age
• 0-14 years
• 15-54 years
• 55 years and above

Route of Administration
• Oral
• Intravenous
• Others

In addition to the revenue predictions for the overall European market and segments, you will also find revenue forecasts for 12 national markets:

By Region
• Europe
• Germany
• UK
• France
• Italy
• Spain
• Russia
• Denmark
• Norway
• Sweden
• Finland
• Netherlands
• Rest of Europe

European Antibiotics Market Report 2021-2031
Need industry data? Please contact us today.

Leading companies and the potential for market growth
Overall revenue for European Antibiotics Market will surpass $xx million in 2020, our work calculates. We predict strong revenue growth through to 2031. Our work identifies which regions hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

Prospects for established firms and those seeking to enter the market– including company profiles for 16 of the major companies involved in the European Antibiotics market. Some of the companies profiled in this report include Abbott Laboratories, Allergan (AbbVie Inc.), Cipla Ltd, Cumberland Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd, GlaxoSmithKline Plc, Novartis International AG, Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd., and Viatris (Mylan).

Key Questions Answered by this Report:
• What is the current size of the overall European Antibiotics market? How much will this market be worth from 2021 to 2031?
• What are the main drivers and restraints that will shape the overall European Antibiotics market over the next ten years?
• What are the main segments within the overall European Antibiotics market? How much will each of these segments be worth for the period 2021 to 2031? How will the composition of the market change during that time, and why?
• What factors will affect that industry and market over the next ten years?
• What are the largest national markets for the European Antibiotics? What is their current status and how will they develop over the next ten years? What are their revenue potentials to 2031?
• How will market shares of the leading national markets change by 2031, and which geographical region will lead the market in 2031?
• Which are the leading companies and what are their activities, results, developments, and prospects?
• What are the main trends that will affect the European Antibiotics market between 2021 and 2031?
• What are the main strengths, weaknesses, opportunities, and threats for the market?
• How will the European Antibiotics market evolve over the forecasted period, 2021 to 2031?
• How will market shares of prominent national markets change from 2021, and which countries will lead the market in 2031, achieving highest revenues and fastest growth?

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else
With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is intended for everybody needing commercial analyses for the European Antibiotics Market and leading companies. You will find data, trends and predictions.

To access the data contained in this document please email contactus@visiongain.com

Buy our report today European Antibiotics Market Report 2021-2031: Forecasts by Drug Class (Cephalosporin, Penicillin, Fluoroquinolone, Macrolide, Carbapenem, Aminoglycoside, Sulfonamide, 7-AC, Others), by Action Mechanism (Cell Wall Synthesis Inhibitors, Protein Synthesis Inhibitors, DNA Synthesis Inhibitors, RNA Synthesis Inhibitors, Mycolic Acid Inhibitors, Others) by Gender (Male, Female), by Age (0-14 Years, 15-54 Years, 55 Years and Above), by Route of Administration (Oral, Intravenous, Others) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Antibiotics Companies AND COVID-19 Recovery Scenarios. Avoid missing out by staying informed – order our report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com

Download sample pages

Complete the form below to download your free sample pages for European Antibiotics Market Report 2021-2031


Download sample pages

Complete the form below to download your free sample pages for European Antibiotics Market Report 2021-2031


Latest Pharma news

Visiongain Publishes Direct-to-Patient Market Report 2021-2031

Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.

21 July 2021

READ

Visiongain Publishes Drug Delivery Technologies Market Report 2021-2031

Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.

20 July 2021

READ

Visiongain Publishes Pharma Contract Sales Market Report 2021-2031

Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.

14 July 2021

READ

Visiongain Publishes Clinical Trial Supply and Logistics Market for Pharma 2021-2031

Digital innovation in clinical trials and renewed focus on home production will ensure a high growth market for supply chain optimisation.

12 July 2021

READ

Categories